Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fu Ke Tiao Jing Ke Li (also known as Fuke Tiaojing Keli) is an approved traditional Chinese medicine (TCM) formulation developed and manufactured by Sinopharm Group Zhijun. It is formulated as oral granules and is indicated for the treatment of irregular menstruation and dysmenorrhea (menstrual abdominal pain). The formulation is a multi-herb mixture containing several traditional Chinese medicinal herbs, including Radix Angelicae Sinensis (Dang Gui), Rhizoma Chuanxiong (Chuan Xiong), Rhizoma Cyperi (Xiang Fu), Rhizoma Atractylodis Macrocephalae (Bai Zhu), Radix Paeoniae Alba (Bai Shao), Radix Paeoniae Rubra (Chi Shao), Rhizoma Corydalis (Yan Hu Suo), Radix Rehmanniae Praeparata (Shu Di Huang), Fructus Jujubae (Da Zao), and Radix et Rhizoma Glycyrrhizae (Gan Cao). It functions primarily by nourishing blood, regulating menstruation, and relieving pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fu Ke Tiao Jing Ke Li.